Idenix Pharmaceuticals (IDIX)

[DewDiligence]

IDIX Announces DDW Presentations

[The most interesting of these presentations (IMHO) is the one on the lack of a drug-drug interaction between Telbivudine and Tenofovir (Viread), which suggests a possible nucleoside+nucleotide treatment regimen using these agents.]

http://biz.yahoo.com/prnews/070418/new084.html?.v=1

>>
Idenix Announces Data Presentations at the 2007 Digestive Disease Week Meeting

Wednesday April 18, 4:05 pm ET

CAMBRIDGE, Mass., April 18 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, announced today that 11 abstracts have been accepted for presentation at the 2007 Digestive Disease Week (DDW) meeting, to be held in Washington D.C. from May 19 to 24. The abstract contents are available on the DDW web site at http://www.ddw.org .

Hepatitis C Abstracts:

Dr. Norman Gitlin, Professor of Medicine, Atlanta Gastroenterology Associations and Emory University, Atlanta, GA, will present "Valopicitabine (NM283) Plus Peg-Interferon Alfa-2a (peg-IFN) in Treatment-Naive Patients With HCV-1 Infection: Preliminary Results At Weeks 24 and 48" in a poster session beginning on Monday, May 21, 2007 at 8:00 a.m. Eastern Daylight Time (EDT).

Dr. Maribel Rodriguez-Torres, President, Fundacion de Investigacion de Diego, Santurce, Puerto Rico, will present "Final Results from a Phase IIA Pharmacokinetic Study of Valopicitabine (NM283) and Peg-IFNa-2b in Patients with Genotype 1 Chronic Hepatitis C" in a poster session beginning on Monday, May 21, 2007 at 8:00 a.m. EDT.

Hepatitis B Abstracts

Dr. Maria Seifer, Director, Biology at Idenix Pharmaceuticals, will present "Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial" in a meeting session on Sunday, May 20, 2007 at 11:15 a.m. EDT.

Dr. Steven Han, Associate Clinical Professor in the Division of Digestive Diseases and the Division of Liver and Pancreas Transplantation and Director of the UCLA Hepatology Clinical Research Center, will present "Telbivudine Globe Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Steven Han will also present "Hepatitis B Patient Survey: Disease Understanding and Compliance in the United States" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Natalie Bzowej, Director of Clinical Hepatology Research at California Pacific Medical Center, will present "A Randomized Trial of Telbivudine vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Elizabeth J. Heathcote, Professor of Medicine at the University of Toronto Western Hospital, will present "Salvage Therapy with Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients from the GLOBE Study" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Yuming Wang, Professor of Infectious Disease, Southwest Hospital, Chongqing, China, will present "A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients with Chronic Hepatitis B: Two- Year Results" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Vinod Rustgi, Co-Director of the Transplant Institute at Georgetown University School of Medicine and Clinical Professor of Medicine at the Medical College of Virginia, will present "A Survey of Hepatitis B Patient Demographics, Disease Characteristics and Management Practice in the United States" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Xiao-Jian Zhou, Director, Clinical Pharmacology at Idenix Pharmaceuticals, will present "Absence of Pharmacokinetic Drug-Drug Interaction Between Telbivudine and Tenofovir" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. David Standring, Senior Vice President, Biology at Idenix Pharmaceuticals, will present "Resistance Determination in Patients Experiencing Virologic Breakthrough Following Telbivudine or Lamivudine Therapy in the International GLOBE Trial" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.
<<